Alefacept

Phase 3Completed

2 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Psoriasis

Conditions

Psoriasis

Trial Timeline

Dec 1, 2001 → Nov 1, 2004

NCT ID

NCT00692172

About Alefacept

Alefacept is a phase 3 stage product being developed by Astellas Pharma for Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00692172. Target conditions include Psoriasis.

What happened to similar drugs?

20 of 20 similar drugs in Psoriasis were approved

Approved (20) Terminated (3) Active (0)

✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved

✅alefaceptAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅Ilumya Injectable ProductSun PharmaceuticalApproved

✅TildrakizumabSun PharmaceuticalApproved

✅Halobetasol Topical LotionSun PharmaceuticalApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01267643	Phase 1	Terminated	May 1, 2011	Apr 16, 2013	Aplastic Anemia
NCT01226420	Phase 2	Terminated	Oct 1, 2010	Aug 1, 2012	Chronic Graft-versus-host Disease
NCT00808223	Phase 2	Completed	Apr 1, 2009	Feb 1, 2012	Psoriasis
NCT00815633	Approved	Terminated	Dec 1, 2008	Mar 1, 2010	Pityriasis Rubra Pilaris
NCT00953329	Approved	Terminated	Feb 1, 2008	Dec 1, 2008	Chronic Plaque Psoriasis
NCT00832585	Approved	Completed	Jan 1, 2008	Oct 1, 2009	Atopic Dermatitis
NCT00658606	Approved	Completed	Oct 1, 2007	Dec 1, 2009	Plaque Psoriasis
NCT00168753	Approved	Completed	Jul 1, 2004	Mar 1, 2005	Moderate to Severe Chronic Plaque Psoriasis
NCT00674063	Phase 3	Completed	Jul 1, 2003	Apr 1, 2004	Chronic Plaque Psoriasis
NCT00692172	Phase 3	Completed	Dec 1, 2001	Nov 1, 2004	Psoriasis

Competing Products

20 competing products in Psoriasis

See all competitors

Product	Company	Stage	Hype Score
PPC-06 400 mg QD + PPC-06 400 mg BID + PPC-06 600 mg + Placebo	Dr. Reddy's Laboratories	Phase 2	32
XP23829 400 mg QD + XP 23829 800 mg QD + XP23829 400 mg BID + Placebo	Dr. Reddy's Laboratories	Phase 2	32
Ixekizumab + Placebo	Eli Lilly	Phase 2	35
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + Placebo	Ventyx Biosciences	Phase 2	21
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous	Eli Lilly	Phase 2	27
Ixekizumab	Eli Lilly	Phase 3	40
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + Placebo	Eli Lilly	Phase 3	40
Placebo + Baricitinib	Eli Lilly	Phase 2	35
CT-P43 + Stelara	Celltrion	Phase 3	40
CT-P17 + EU-approved Humira	Celltrion	Phase 3	40
CT-P55 + EU-approved Cosentyx	Celltrion	Phase 3	44
AMG 139	AstraZeneca	Phase 1	29
alefacept + polyvalent pneumococcal vaccine	Astellas Pharma	Approved	43
alefacept	Astellas Pharma	Phase 2	35
Tacrolimus Cream	Astellas Pharma	Phase 3	40
alefacept	Astellas Pharma	Phase 3	40
peficitinib + Placebo	Astellas Pharma	Phase 2	35
Amevive exposure	Astellas Pharma	Pre-clinical	18
alefacept + placebo	Astellas Pharma	Phase 3	40
alefacept	Astellas Pharma	Approved	43